1 bear market blunder investors are still making

Focusing on the short term could lead to long-term losses.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

A lot has changed in the past year in the stock market as growth stocks have been crashing hard, with the Nasdaq dropping by 15%. Even the more stable S&P 500 has fallen 6%. Concerns about inflation and a possible recession are weighing on investors.

But despite these fears, many investors are still making potentially costly mistakes by focusing on current trends and hopping on stocks that simply aren't good buys. Here's what I mean.

Investors are taking on too much risk

Billionaire investors Warren Buffett and Charlie Munger have compared the markets to a gambling parlor. This could explain why a struggling retailer like Bed Bath & Beyond, which has incurred losses of more than $866 million over the trailing 12 months, can skyrocket more than 45% within a single trading session as it did last week.

Another example of that gambler mentality is the desire to invest in companies that have monkeypox treatments or vaccines. Shares of SIGA Technologies, which makes a monkeypox treatment, have jumped close to 260% in just the past six months. Bavarian Nordic is up 64% during that period as investors are hopeful about its monkeypox vaccine. Meanwhile, the S&P 500 has declined 4% over that stretch.

While some investors are earning quick profits on this short-term trading, buying at the wrong time could lead to significant losses. There's also the danger of hanging on too long with these types of stocks.

What's hot today could be a dud next year

If you end up buying a stock based on a short-term trend, the risk is that when the frenzy calms down, you could be left holding the bag, with an investment that doesn't look nearly as exciting as it once did.

COVID-19 vaccine maker Moderna (NASDAQ: MRNA) is a good example. Last year, its stock price jumped 143% as rising COVID case numbers made the healthcare stock a hot buy. This year, the company expects to generate $21 billion in revenue from its vaccine.

But beyond that, there are big question marks surrounding the business. Moderna's focus on COVID has resulted in a lack of diversification for the company, and that has made investors wary of the stock. It's down 40% year to date.

It's a similar story for rival COVID vaccine maker Novavax, which in 2020 jumped by a whopping 2,700%. But with its COVID vaccine not obtaining Emergency Use Authorization until just last month and the company slashing its sales forecast for 2022 in half, its shares are down 75% this year.

Investors shouldn't overlook fundamentals

The key takeaway for investors is to focus on long-term trends and a company's business prospects beyond just the short term. While SIGA Technologies might be a hot buy this year, it could give back many of its gains if monkeypox cases subside and the disease doesn't derail the global economy the way COVID has over the past few years.

More stable healthcare stocks, such as Merck and AbbVie, have proved to be sound investments and have outperformed the markets this year, with returns of 19% and 4%, respectively. Although they might not generate sky-high returns in the short term, they also won't jeopardize your savings and put your portfolio at great risk.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

David Jagielski has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on International Stock News

Woman on her phone with diagrams of tech sector related elements linking with each other.
Share Market News

Which magnificent 7 stock would I buy today with $5,000?

One stands above the rest.

Read more »

Smiling man with phone in wheelchair watching stocks and trends on computer
International Stock News

Important dates to watch for US stocks in July

Keep an eye on these upcoming dates that could impact your portfolio

Read more »

Hand with AI in capital letters and AI-related digital icons.
International Stock News

5 Leading Tech Stocks to Buy in 2025

Technology stocks have been the driving force in the market for more than the past decade.

Read more »

Arrows pointing upwards with a man pointing his finger at one.
International Stock News

These 3 tech stocks are unstoppable monsters

These technology heavyweights still have years of upside ahead of them.

Read more »

Delighted adult man, working on a company slogan, on his laptop.
International Stock News

Is Nvidia a no-brainer bargain buy right now?

Nvidia is probably the hottest artificial intelligence stock on the planet.

Read more »

Hologram of a man next to a human robot, symbolising artificial intelligence.
International Stock News

Nvidia CEO Jensen Huang thinks Tesla has a multitrillion-dollar artificial intelligence (AI) opportunity up its sleeve (Hint: it's not robotaxi)

Tesla has several ambitions rooted in artificial intelligence (AI) to grow beyond the core car business.

Read more »

AI written in blue on a digital chip.
International Stock News

Better artificial intelligence stock: Palantir vs. Nvidia

Here's a look at Palantir and Nvidia to arrive at an answer.

Read more »

Couple watching Netflix.
International Stock News

Should you buy, sell, or hold Netflix stock in 2025?

The streaming stock is up an impressive 38% in 2025.

Read more »